

Special Issue

A Deeper Dive into Signaling Pathways in Cancers

Message from the Guest Editor

Most targeted drugs for cancer therapy have been developed to block aberrant signaling transmitted from the cell surface to the nucleus in tumor cells. Signaling networks in cancers *in vivo* are intricate and complex, however, involving the interplay and crosstalk of signaling pathways as well as intercellular signaling between different cell types. The importance of signaling between immune cells and tumor cells is evident from the considerable success of immune checkpoint inhibitors. Intercellular signaling between tumor cells and cancer-associated fibroblasts (CAFs) in the microenvironment is implicated in cancer growth, progression, metastasis, and drug resistance, while signaling-to-chromatin pathways regulate the transcriptional and epigenetic landscape in cancers leading to the development of epigenetic agents such as DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors. This Special Issue of *Cancers* will provide a comprehensive overview of divergent signals involved in cancer pathogenesis with a focus on therapeutic approaches aimed at these aberrant signals and explore the possibilities of next-generation cancer therapy.

Guest Editor

Dr. Mari Masuda

Department of Proteome Analysis, National Cancer Center Research Institute, Tokyo 104-0045, Japan

Deadline for manuscript submissions

closed (31 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/93359

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)